ArticleCell death discovery2026
USP13 facilitates pressure overload induced vascular remodeling and phenotypic transition of VSMCs via deubiquitinating Beclin-1.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pressure overload-induced vascular remodeling is a complex physiological response that can result in detrimental cardiovascular diseases. Ubiquitination plays a critical role in this process; however, the role and specific mechanism of deubiquitinating enzyme USP13 in vascular remodeling remain poorly understood. Male C57BL/6J mice were subjected to pressure overload via transverse aortic constriction to investigate USP13's effects in arterial remodeling. Primary vascular smooth muscle cells (VSMCs) were employed to investigate the role of USP13 on VSMC phenotype transition and potential mechanism. Mechanical stretch increased USP13 protein levels in vascular tissues while downregulating Acta2. Similarly, in both rat and human aortic VSMCs, PDGF-BB treatment significantly raised USP13 mRNA and protein levels. Notably, USP13 overexpression worsened arterial wall thickening in TAC mice and decreased Acta2 levels, whereas Spautin-1 treatment had a protective effect. At the cellular level, knocking down USP13 mitigated PDGF-BB-induced VSMC proliferation, as indicated by lower PCNA levels and reduced EdU (+) cell counts. Additionally, USP13 overexpression enhanced VSMC migration, demonstrated by scratch and transwell experiments. USP13 also aggravated PDGF-BB-induced downregulation of ACTA2 and Transgelin while promoting OST elevation. Mechanistically, USP13 interacted with Beclin-1, facilitating its deubiquitination and promoting autophagic flux, as shown by increased LC3 II/I ratios and decreased p62 levels. Moreover, BHLHE40 was explored as a new transcription factor of USP13, and BHLHE40 can regulate VSMCs proliferation and migration by transcriptionally activating USP13. In conclusion, our findings elucidate the role of USP13 in vascular remodeling under pressure overload, suggesting that targeting USP13 may offer therapeutic potential for pathological vascular disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.